ArticleProblemy endokrinologii2026
[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].
Article in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMultiple endocrine neoplasia syndrome type 1 (MEN-1) is a rare, autosomal dominant disorder resulting from inactivating mutations in the MEN1 gene. It demonstrates high penetrance, with the "classic triad" of manifestations comprising primary hyperparathyroidism (PHPT), gastrointestinal neuroendocrine neoplasms (NEN), and pituitary adenomas. Diagnosis relies on clinical, familial, and genetic criteria. However, significant phenotypic variability and the lack of a clear genotype-phenotype correlation complicate early diagnosis.
aimTo investigate the clinical-epidemiological, laboratory-instrumental, and genetic characteristics of familial MEN-1 in the Russian population. MATERIALS AND
methodsWe conducted a single-center, single-stage study (2015-2025) at the Endocrinology Research Centre enrolling 102 genetically confirmed MEN-1 patients from 43 families. Participants were stratified by age at PHPT onset (≤18 years, 19-40 years, and >40 years) and MEN1 mutation type/location. We compared groups using calcium-phosphorus metabolism parameters, disease progression patterns, PHPT surgical outcomes, and genotype-phenotype correlations.
resultsCohort baseline characteristics (sex, manifestations) were comparable (p>0,05), but we observed significant differences in NEN onset age (p<0,001) and a trend toward higher pituitary adenoma prevalence (p=0,003). Exon 10 mutation were associated with a 7,7-fold increased pituitary adenoma risk (OR=7,7; p=0,006), though mutation type did not predict broader phenotype. Groups did not differ in multiglandular involvement, surgical outcomes, or histopathology (p>0,05).
conclusionMEN-1 exhibits marked clinical heterogeneity in the Russian population, with exon 10 mutations significantly increasing pituitary adenoma risk. Early-onset PHPT predicts earlier NEN and pituitary adenoma development. These findings support proactive genetic screening and risk-stratified monitoring for MEN-1 families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.